INDP — Indaptus Therapeutics Share News
0.000.00%
Last trade - 00:00- $459.21m
- $447.65m
Brief: Indaptus Therapeutics Activates Emory Winship Cancer Institute As Trial Site In INDP-D101
Brief: Indaptus Therapeutics Doses First Subject In Its Ongoing Phase 1 Open Label Clinical Trial Of Decoy20 In Patients With Advanced Solid Tumors
Brief: Indaptus Therapeutics Inc - On Feb 13 Board Increased Its Size To Provide For A Total Of Nine Directors Authorized To Serve On Board
Brief: Indaptus Therapeutics Activates Morristown Medical Center As New Clinical Trial Site For Treatment Of Advanced Solid Tumors
Brief: Indaptus Therapeutics Enteres Purchase Agreement With Lincoln Park
U.S. STOCKS ON THE MOVE-Apparel stocks, copper and silver miners
U.S. STOCKS ON THE MOVE-Alphabet, Moderna, chip stocks
Indaptus gains as co initiates tumor drug trial
Brief: Indaptus Therapeutics Announces Initiation Of First-In-Human, Open Label, Dose Escalation And Expansion Phase 1 Trial Of Decoy20 In Patients With Advanced Solid Tumors
Brief: Indaptus Therapeutics Reports Third Quarter 2022 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Skechers, Spotify, Twitter
Brief: Indaptus Therapeutics Inc Files For Mixed Shelf Of Upto $200 Million - SEC Filing
Brief: Indaptus Therapeutics Inc - Company Had Cash, Cash Equivalents And Short-Term Investments Of Approximately $33.0 Mln
Brief: Indaptus Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million
U.S. STOCKS ON THE MOVE-Synopsys, Cato, Canaan
Indaptus Therapeutics rises on FDA nod for cancer therapy trial
Brief: Indaptus Therapeutics Announces FDA Clearance Of INDA To Initiate Phase 1 Clinical Trial Of DECOY20 In Solid Tumors
Brief: Indaptus Therapeutics Reports First Quarter 2022 Financial Results
Brief: Indaptus Therapeutics Reports Q4 Results